Shield Therapeutics starts trading on the OTCQX, Tectonic Metals and Alan Green on 3 Small Caps
On today's Vox Markets Podcast: Shield Therapeutics starts trading on the OTCQX, Tectonic Metals and Alan Green on 3 Small Caps
Tim Watts, CEO of Shield Therapeutics #STX explains why they listed the company's shares on the OTCQX in the United States.
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
Tony Reda, Founder, President, CEO & Director Tectonic Metals ("TECT" on TSX Venture, “TETOF” on OTCQB and “T15B” in Frankfurt) discusses the business and upcoming milestones.
Tectonic is focused on the acquisition, exploration, discovery and development of mineral resources from district-scale projects in politically stable jurisdictions that have the potential to host world-class orebodies. Tectonic Metals is traded under the ticker symbol “TECT” on TSX-V, “TETOF” on OTCQB and “T15B” in Frankfurt.
(Interview starts 7 minutes)
Alan Green CEO of Brand Communications talks about:
(Interview starts 17 minutes 14 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.